MTSR - NASDAQ
Metsera, Inc.
$70.50
+0.0000%Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
At a Glance
Live Snapshotmtsr
Total Non-Current Assets
Last Annual Value
91.86M
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Metsera, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Metsera, Inc. NASDAQ:MTSR | 91.86M | -0.1% | N/A | N/A | |
 Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR | 434.66M | 7.9% | 6.0% | 27.7% | |
 Arcellx, Inc. NASDAQ:ACLX | 141.81M | 9.2% | 54.8% | N/A | |
 Axsome Therapeutics, Inc. NASDAQ:AXSM | 100.82M | 6.3% | 140.0% | 85.1% | |
 Cytokinetics, Incorporated NASDAQ:CYTK | 507.56M | 37.3% | 10.7% | 46.0% | |
 Nuvalent, Inc. NASDAQ:NUVL | 20.28M | 50.9% | 44.7% | N/A | |
 Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM | 14.28M | -16.4% | -7.5% | 28.5% | |
 Vaxcyte, Inc. NASDAQ:PCVX | 1.42B | 65.7% | 83.6% | N/A |
Metsera, Inc. Fair Value Envelope
Related Guides
Continue your MTSR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.